TME PHARMA competitors & alternatives

Biotechnology

Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.

ME THERAPEUTICS HOLDINGS INC.BiotechnologyCanada

72% match

Biotechnology

ME Therapeutics Holdings Inc. is a clinical-stage biotechnology company that discovers and develops immuno-oncology therapeutics designed to reprogram immune cells in vivo. Its pipeline aims to activate the body's immune system to recognize and fight cancer cells.

Biotechnology

Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.

Altido TherapeuticsBiotechnologyUnited States

68% match

Biotechnology

Altido Therapeutics is a clinical-stage biotechnology company located in Waltham, Massachusetts that is advancing a dual-mechanism CAR-TEAM immunotherapy platform to treat glioblastoma.

Biotechnology

Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.

Biotechnology

BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.

Biotechnology

Phenomic AI Inc. is a biotechnology company developing novel antibody-based therapies directed against the tumor stroma to improve patient outcomes.

MaaT PharmaMAAT · BiotechFrance

67% matchPublic

Similar biotech company

MaaT Pharma is a clinical-stage biotechnology company that develops microbiome-based therapeutics to improve treatment outcomes and survival rates for cancer patients. The company focuses on restoring microbiome function to address life-threatening diseases using a full ecosystem approach and AI-powered drug development.

Alixia, Inc.BiotechnologyUnited States

67% match

Biotechnology

Alixia, Inc. is a biotechnology company that develops therapeutics targeting tumor ecosystems to address cancer drug resistance and complex, chronic diseases. The company utilizes a research platform integrating biology, biophysics, computational chemistry, and clinical input to discover lead compounds that disrupt metabolic and inflammatory triggers within the tumor microenvironment.

Gibson Oncology, LLCBiotechnologyUnited States

67% match

Biotechnology

Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.

Medicenna Therapeutics Corp.MDNAF · BiotechToronto, Canada

66% matchPublic

Similar biotech company

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Treovir, LLCBiotechnologyUnited States

66% matchPrivate

Biotechnology

Treovir is a clinical-stage biotechnology company that develops therapies for pediatric brain tumors. Its lead product candidate, G207, is an oncolytic virus therapy currently undergoing clinical trials to treat conditions such as pediatric recurrent glioblastoma.